Plaque Psoriasis Treatment is Launched

Wynzora is a cream-based, fixed dose combination of calcipotriene and betamethasone for topical treatment of psoriasis.

EPI Health and MC2 Therapeutics have announced the commercial availability in the United States of Wynzora Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%) for the topical treatment of plaque psoriasis in adults 18 years of age or older.

Wynzora is a cream-based, fixed-dose combination of calcipotriene and betamethasone dipropionate. It uses the PAD Technology, which enables stability of both calcipotriene and betamethasone dipropionate in a aqueous formulation and works to clear plaques without the messiness of conventional formulations.

“Calcipotriene and betamethasone dipropionate are well-established molecules for the treatment of plaque psoriasis, with proven efficacy, safety and tolerability. Until now they could not be combined into an aqueous cream, which is less greasy and more user-friendly than other formulations,” John Koo, M.D., professor of dermatology at University of California San Francisco medical center and co-director, UCSF Psoriasis Treatment Center, said in a statement.

According to the National Psoriasis Foundation, psoriasis affects more than 3% of the U.S. adult population, or 7.5 million people. One in three of these will develop psoriatic arthritis, a chronic, inflammatory disease of the joints and where tendons and ligaments connect to bone.